SCHEMBL2034080

SCHEMBL2034080

CCC(OC)(OC)C(=O)C=CN(C)C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.48
MAPT P10636 5/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
KMT2A Q03164 3/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.32
GAA P10253 2/20 0.32
KDM4E B2RXH2 1/20 0.32
RECQL P46063 2/20 0.32
POLB P06746 2/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
CYP1A2 P05177 2/20 0.30
CYP2C19 P33261 2/20 0.30
HTT P42858 1/20 0.30
ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2034079 1.00 TDP1 (0.48) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL13449494 0.74 TDP1 (0.54) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL751104 0.74 TDP1 (0.54) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL751103 0.74 TDP1 (0.54) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL14435647 0.74 TDP1 (0.59) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL13221154 0.68 TDP1 (0.62) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL678566 0.68 TDP1 (0.62) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL6977513 0.68 TDP1 (0.62) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL24759814 0.67 TDP1 (0.50) TDP1MAPTALDH1A1HPGDKMT2A
SCHEMBL17361336 0.67 TDP1 (0.50) TDP1MAPTALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP disclosed
US-8952001-B2 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME CORP. (US) 2015-02-10 US disclosed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP disclosed
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-10-18 US disclosed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS HCN1, HCN3, HCN2 TDP1 3489/4885MAPT 1615/4885ALDH1A1 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.